← FDA Drug Approvals (Drugs@FDA)

GABAPENTIN

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: RUBICON RESEARCH · Approved 2023-01-18

Drug application

FDA Application #

ANDA216492

Application type

Abbreviated New Drug Application (Generic)

Brand name

GABAPENTIN

Generic name

GABAPENTIN

Active ingredients

GABAPENTIN

Dosage form

SOLUTION

Route

ORAL

Marketing status

Prescription

Sponsor

RUBICON RESEARCH

Manufacturer

Advagen Pharma Ltd

First approval

2023-01-18

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown